

# Maeve Jones-O'Connor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2637801/publications.pdf>

Version: 2024-02-01

19  
papers

930  
citations

933264

10  
h-index

839398

18  
g-index

24  
all docs

24  
docs citations

24  
times ranked

1348  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	1.0	212
2	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	1.2	179
3	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
4	Misclassification of Myocardial Injury as Myocardial Infarction. <i>JAMA Cardiology</i> , 2019, 4, 460.	3.0	80
5	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
6	Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. <i>EClinicalMedicine</i> , 2020, 26, 100504.	3.2	44
7	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 32.	0.4	42
8	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
9	The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm. <i>JACC: CardioOncology</i> , 2021, 3, 101-109.	1.7	31
10	Preventive Management of Nonobstructive CAD After Coronary CT Angiography in the Emergency Department. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 437-448.	2.3	20
11	Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007440.	0.9	16
12	Sex Differences in Patient Characteristics, Treatment Strategies, and Outcomes for Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3230-3232.	1.2	10
13	Underutilization of Cardiac Rehabilitation for Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2005-2007.	1.2	10
14	Application of the GRACE, TIMI, and TARRACO Risk Scores in Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 344-345.	1.2	9
15	The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. <i>PLoS ONE</i> , 2022, 17, e0265767.	1.1	9
16	Outcomes of a smartphone-based application with live health-coaching post-percutaneous coronary intervention. <i>EBioMedicine</i> , 2021, 72, 103593.	2.7	8
17	Home Time After Discharge Among Patients With Type 2 Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2020, 9, e015978.	1.6	7
18	The Intersection of Type 2 Myocardial Infarction and Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e020849.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 38.	0.4	1